A Phase 1 interventional study of Lorcaserin and Placebo Oral Tablet in Cocaine Dependence, sponsored by Mclean Hospital. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-10-20.
Sponsored by Mclean Hospital · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 365 studies in Cocaine-Related Disorders with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Cocaine-Related Disorders · United States.
Among the 365 studies in Cocaine-Related Disorders with a site in United States, this one is the 269th largest by enrollment of the 337 interventional ones that give a count, is one of 3 that started in 2018, is one of 86 in phase 1, and was the 336th registered.
416 studies on the registry are indexed under Cocaine-Related Disorders; 12 are open to participants now.
Browse Cocaine-Related Disorders studies →7 of the 365 studies in Cocaine-Related Disorders with a site in United States are open now. Recruiting first, the newest first:
New York State Psychiatric Institute · Sites in United States
Ages 22–65
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–60
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+
DynamiCare Health · Sites in United States
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 21–69
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Cocaine-Related Disorders studies recruiting now, 5 (45%) set no upper age limit and 6 (55%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
365 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 97 · Phase 2 180 · Phase 3 22 · Phase 4 11
First in 1987; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 37 across the 337 interventional studies, 24 across the 25 observational. Of the 326 that completed or were terminated, 117 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 365 have an industry lead sponsor. The 10 most frequent:
Mclean Hospital is the lead sponsor of 185 studies on the registry; 31 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 12 (80%) have results posted.
Mclean Hospital has 1 study filed under Cocaine-Related Disorders — fewer than ten, so there is no comparison to draw.
3 of the studies in Cocaine-Related Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04884594W. Michael HootenAAV8-hCocH for Cocaine Use Disorder | 2026-12 |
| NCT02455479Weill Medical College of Cornell UniversitySafety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals | 2026-12 |
| NCT07092059DynamiCare HealthSmartphone Services for Stimulant Use Disorder | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 365 studies in Cocaine-Related Disorders with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In the United States, 1.5 million people abuse cocaine leading to a host of negative health and economic consequences, yet no FDA approved treatment exists. To develop effective treatments, the following must be considered: 1) do potential medications ameliorate brain disruptions associated with cocaine use? 2) are multiple, targeted treatments necessary? To meet these goals, innovative multi-modal neuroimaging will be used to determine whether rebalancing the serotonergic (5-HT) system reduces cocaine cue reactivity, impulsivity, and normalizes related neurochemistry and brain connectivity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo Oral Tablet
Drug: Lorcaserin
10 mg acute administration of lorcasein
Placebo
Influence of lorcaserin on fMRI measured brain-reactivity to drug cues.
Time frame: fMRI measures will be gathered on scanning visits 1 and 2 (approx 1 week apart)
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2018 to primary completion in Oct 2018, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lorcaserin